| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 10/04/2001 | US20010027250 Cell line derived enzyme replacement therapy for glycogen storage disease; purity; free of human immunodeficiency virus |
| 10/04/2001 | US20010027214 Stable and nonhygroscopic salts to form tablets, capsules, powders, etc. suitable for dietary/nutritional humans supplements and a feed supplement for veterinary medicine; high-energy metabolism; cardiovascular systems |
| 10/04/2001 | US20010027211 Anticarcinogenic, -inflammatory and -proliferative agents; viricides; bactericides; vascular restenosis, autoimmune diseases; psoriasis; anticolesterol and -lipemic agents |
| 10/04/2001 | US20010027207 Modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation; anticarcinogenic, -diabetic, -proliferative and -inflammatory agents; vascular system disorders |
| 10/04/2001 | US20010027200 PPARgamma modulators |
| 10/04/2001 | US20010027193 1-Diarylmethyl-4-alkyl or alkylsulfonylalkyl-azetidines; cannabinoid receptor antagonists; nervous system disorders (CNS); cardiovascular and glandular disorders; drug abuse; psychological disorders; |
| 10/04/2001 | US20010026934 Conversion of compactin to pravastatin by actinomadura |
| 10/04/2001 | US20010026814 Composition for and method of reducing low density lipoprotein cholesterol concentration |
| 10/04/2001 | US20010026794 Two heterologous DNA encoding gene products; prolonged half-life |
| 10/04/2001 | EP1138692A1 Fragments of human chorionic gonadotropin (hcg) as immunoregulator |
| 10/04/2001 | EP1138680A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors |
| 10/04/2001 | EP1138678A2 Process for making N-((4-phenyl) methylphenyl) piperazines |
| 10/04/2001 | EP1138674A1 Crystalline forms of 3-(2,4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3h-benzimidazole-5-carboxamide |
| 10/04/2001 | EP1138329A2 Composition containing 5-Methyl-1-phenyl-2-(1 H)-pyridone for reparation and prevention of fibrotic lesions |
| 10/04/2001 | EP1138326A1 Use of synthetic triglycerides based on conjugated linoleic acid in the preparation of agents for the treatment of catabolic conditions |
| 10/04/2001 | EP1138325A1 Use of synthetic triglycerides based on conjugated linoleic acid in the preparation of agents aiding tumour treatment |
| 10/04/2001 | EP1138321A2 Solid oral dosage forms with sustained drug release and high mechanical stability |
| 10/04/2001 | EP1137948A1 Methods and compositions to lower plasma cholesterol levels |
| 10/04/2001 | EP1137783A2 Beta-1,3-galactosyltransferase homologs |
| 10/04/2001 | EP1137774A2 Grnf4, a gdnf-related neurotrophic factor |
| 10/04/2001 | EP1137773A2 Growth factor homolog zvegf3 |
| 10/04/2001 | EP1137762A1 Treatment of pompe's disease |
| 10/04/2001 | EP1137667A2 Analogues of glp-1 |
| 10/04/2001 | EP1137666A1 Glp-1 analogues |
| 10/04/2001 | EP1137658A1 METHODS OF MODULATING TUMOR NECROSIS FACTOR $g(a)-INDUCED EXPRESSION OF CELL ADHESION MOLECULES |
| 10/04/2001 | EP1137656A1 31 human secreted proteins |
| 10/04/2001 | EP1137646A1 Derivative of paroxetine |
| 10/04/2001 | EP1137635A1 N-substituted 2-cyanopyrrolidines |
| 10/04/2001 | EP1137621A1 Aldose reductase inhibitors and pharmaceutical compositions |
| 10/04/2001 | EP1137438A1 Formulation with an improved therapeutic range, containing nucleotide synthesis inhibitors |
| 10/04/2001 | EP1137431A1 Pharmaceutical compositions containing insulin |
| 10/04/2001 | EP1137419A1 Uses of 1-amino-3-(n,n-dimethylamino)-propylidene-1,1-bisphosphonic acid |
| 10/04/2001 | EP1137418A2 METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY |
| 10/04/2001 | EP1137417A1 Use of selected modulators of p2 purinoceptors for the prevention of damage and mortality caused by global cerebral ischemia and ischemia-reperfusion |
| 10/04/2001 | EP1137416A1 Use of long-chain n-alkyl derivatives of deoxynojirimycin for the manufacture of a medicament for the treatment of glycolipid storage diseases |
| 10/04/2001 | EP1137410A1 Novel 4-dedimethy laminotetra cycline derivatives |
| 10/04/2001 | EP1137408A1 Agent for lowering endothelin levels |
| 10/04/2001 | EP1137402A1 Phospholipid compositions |
| 10/04/2001 | EP1137401A1 Administration of neurotrophic agents to the central nervous system |
| 10/04/2001 | EP1123094A4 Therapeutic compositions (ii) |
| 10/04/2001 | EP0981282A4 Process for preparing a nutritional supplement |
| 10/04/2001 | EP0891326B1 Novel vitamin d analogues |
| 10/04/2001 | EP0821665B1 Cyclobutane derivatives as inhibitors of squalene synthase and protein farnesyltransferase |
| 10/04/2001 | DE19947154A1 Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use |
| 10/04/2001 | CA2429196A1 Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto |
| 10/04/2001 | CA2404913A1 Sterol ester compositions |
| 10/04/2001 | CA2404901A1 Composition and method for intervening neuronal death using sulfasalazine |
| 10/04/2001 | CA2404780A1 Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
| 10/04/2001 | CA2404626A1 Novel piperazine derivatives |
| 10/04/2001 | CA2404570A1 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 10/04/2001 | CA2404528A1 Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof |
| 10/04/2001 | CA2404493A1 A method for screening for autoimmune disease by identifying polymorphisms in il-12 p40 |
| 10/04/2001 | CA2404478A1 Glycosaminoglycans derived from the k5 polysaccharide having high anticoagulant and antithrombotic activity and process for their preparation |
| 10/04/2001 | CA2404461A1 Human g-protein coupled receptors |
| 10/04/2001 | CA2404445A1 Tricyclic protein kinase inhibitors |
| 10/04/2001 | CA2404411A1 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 10/04/2001 | CA2404231A1 Methods of treating diseases with activated protein c |
| 10/04/2001 | CA2403857A1 Anti-angiogenic and anti-tumor properties of matin and other laminin domains |
| 10/04/2001 | CA2403800A1 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 10/04/2001 | CA2403787A1 Il-8 receptor antagonists |
| 10/04/2001 | CA2403515A1 Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains |
| 10/04/2001 | CA2403297A1 Docosahexaenoic acid as retinoid x receptor and uses thereof |
| 10/04/2001 | CA2402780A1 Insulin and igf-1 receptor agonists and antagonists |
| 10/04/2001 | CA2402769A1 Ceramide derivatives and method of use |
| 10/04/2001 | CA2402735A1 Human transcription factors |
| 10/04/2001 | CA2402472A1 2,3,4,5-tetrahydro-1h-¬1,4|diazepino¬1,7a|indole compounds |
| 10/04/2001 | CA2374911A1 G-protein coupled receptors |
| 10/03/2001 | CN1315964A Protein/polypeptide-K obtained from i(momordica charantia) and process for extraction thereof |
| 10/03/2001 | CN1315949A Salts of paroxetine |
| 10/03/2001 | CN1315946A Process for selective lactonization |
| 10/03/2001 | CN1315859A Substances having antiobese and visceral fat-reducing functions and utilization thereof |
| 10/03/2001 | CN1315856A Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
| 10/03/2001 | CN1315835A Antioxidant composition comprising acetyl L-carnitine and alpha-lipoic acid |
| 10/03/2001 | CN1315402A Polypeptide-human amyloid precursor protein bindin 14 and polynucleotide for coding it |
| 10/03/2001 | CN1315320A Ether and amide compounds as medicide for treating glycuresis and preparing process thereof |
| 10/03/2001 | CN1315203A Natural health-care tea for diabetics and its preparing process |
| 10/03/2001 | CN1315199A Medicine for regulating blood fat and reducing plasma fibrin |
| 10/03/2001 | CN1315188A Buccal lozenge of superfine notoginseng powder |
| 10/03/2001 | CN1315184A Oral liquid for losing weight and its preparing process |
| 10/03/2001 | CN1072014C Fat reducing pill and producing technology thereof |
| 10/02/2001 | US6297381 Inhibit the release of inflammatory cytokines such as interleukin-1 and tumor necrosis factor, ureas or thioureas substituted by a pyrrole or thiophene |
| 10/02/2001 | US6297359 Polypeptide for use in the treatment of diabetes, dietetics, hypertension and premature atherosclerosis |
| 10/02/2001 | US6297269 Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors |
| 10/02/2001 | US6297261 Potent chloride channel blockers; treatment of sickle cell anemia, brain edema following ischaemia or tumors, diarrhea, hypertension (diuretic), osteoporosis, and for the reduction of the intraocular pressure |
| 10/02/2001 | US6297260 Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use |
| 10/02/2001 | US6297238 3-aryl pyrazoles with 4,5(3,4)-bicyclic ring fusion which are inhibitors of protein kinases particularly tyrosine kinases and serine/threonine kinases |
| 10/02/2001 | US6297226 Treating a disease or a condition in a mammal treatable by inhibiting the activity of a monoamine oxidase |
| 10/02/2001 | US6297043 Molecular formula of c28 h20 o12; culture product from streptomyces which inhibits glucose-6-phosphate translocase; antidiabetic agents |
| 10/02/2001 | US6296872 Tablet composition of N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine |
| 10/02/2001 | CA2234567C Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents |
| 10/02/2001 | CA2076647C Branched fructo-oligosaccharides, a method for obtaining them and uses of products containing them |
| 09/27/2001 | WO2001071358A1 Method of screening for inhibitors of osteopontin |
| 09/27/2001 | WO2001071342A2 Identification of mast cell/basophil activation inhibitors |
| 09/27/2001 | WO2001071005A2 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| 09/27/2001 | WO2001071004A2 Proteases |
| 09/27/2001 | WO2001070998A1 Talaromyces emersonii beta-glucanases |
| 09/27/2001 | WO2001070989A2 Genetically modified plants and plant cells comprising heterologous heavy metal transport and complexation proteins |
| 09/27/2001 | WO2001070978A2 Polypeptides and nucleic acids encoding same |
| 09/27/2001 | WO2001070977A2 Fibroblast growth factor receptor-like molecules and uses thereof |
| 09/27/2001 | WO2001070975A1 Novel melanin concentrating hormone receptor |